Literature DB >> 1675057

Expression of c-erbB-2 in human pancreatic adenocarcinomas.

T M Williams1, D B Weiner, M I Greene, H C Maguire.   

Abstract

The c-erbB-2 (neu) gene encodes a transmembrane phosphoglycoprotein (p185erbB-2) which resembles a growth factor receptor-like molecule closely related to the epidermal growth factor receptor. Overexpression of c-erbB-2 induces cell transformation in vitro. Poorer survival rates and elevated recurrence rates following treatment have been shown in patients whose breast adenocarcinomas demonstrate increased c-erbB-2 expression. Using immunoprecipitation and immunoperoxidase staining, we surveyed human cell lines for p185erbB-2. Cell lines from most tumor types (e.g. lymphomas, neuroblastomas, melanomas) demonstrated negligible p185erB-2; however, 3 of 6 pancreatic cell lines overexpressed c-erbB-2. Southern blot analysis revealed that c-erbB-2 was amplified in two of these cell lines and was both rearranged and amplified in one of them. Based on these findings, we examined tissue sections from archival specimens of primary human pancreatic adenocarcinomas. A substantial proportion of specimens had increased p185erbB-2, as judged by increased immunostaining of the tumor cells. In such pancreatic tumors p185erbB-2 may contribute to the malignant phenotype and could provide a target for immunodiagnostic or immunotherapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1675057     DOI: 10.1159/000163614

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  21 in total

1.  Aberrant signaling pathways in pancreatic cancer: a two compartment view.

Authors:  Angela L McCleary-Wheeler; Robert McWilliams; Martin E Fernandez-Zapico
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

2.  Protein quantification from complex protein mixtures using a proteomics methodology with single-cell resolution.

Authors:  H T Zhang; J E Kacharmina; K Miyashiro; M I Greene; J Eberwine
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

Review 3.  Non-invasive, ultra-sensitive, high-throughput assays to quantify rare biomarkers in the blood.

Authors:  Jaclyn A Freudenberg; Kathryn Bembas; Mark I Greene; Hongtao Zhang
Journal:  Methods       Date:  2008-06-23       Impact factor: 3.608

Review 4.  The use of molecular technology in the differentiation of pancreatic cancer and chronic pancreatitis.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1998-04

5.  Ductal adenocarcinoma of the pancreas: Expression of growth factor receptors, oncogenes and suppressor genes, and their relationship to pathological features, staging and survival.

Authors:  Antonio Lozano-Leon; Begona Vieites Perez-Quintela; Julio Iglesias-García; Jose Lariño-Noia; Evaristo Varo; Jeronimo Forteza; J Enrique Domínguez-Muñoz
Journal:  Oncol Lett       Date:  2010-11-23       Impact factor: 2.967

Review 6.  Precursors to pancreatic cancer.

Authors:  Ralph H Hruban; Anirban Maitra; Scott E Kern; Michael Goggins
Journal:  Gastroenterol Clin North Am       Date:  2007-12       Impact factor: 3.806

7.  Evaluation of serum HER2-ECD levels in patients with gastric cancer.

Authors:  Katsunobu Oyama; Sachio Fushida; Tomoya Tsukada; Jun Kinoshita; Toshifumi Watanabe; Masatoshi Shoji; Shinichi Nakanuma; Koichi Okamoto; Seisho Sakai; Isamu Makino; Keishi Nakamura; Hironori Hayashi; Masafumi Inokuchi; Hisatoshi Nakagawara; Tomoharu Miyashita; Hidehiro Tajima; Hiroyuki Takamura; Itasu Ninomiya; Hirohisa Kitagawa; Takashi Fujimura; Ryousuke Tajiri; Akishi Ooi; Tetsuo Ohta
Journal:  J Gastroenterol       Date:  2014-02-21       Impact factor: 7.527

8.  Frequent expression of genes for receptor tyrosine kinases and their ligands in human pancreatic cancer cells.

Authors:  T Oikawa; J Hitomi; A Kono; E Kaneko; K Yamaguchi
Journal:  Int J Pancreatol       Date:  1995-08

9.  Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies.

Authors:  G D Lewis; I Figari; B Fendly; W L Wong; P Carter; C Gorman; H M Shepard
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

10.  Inverse regulation of human ERBB2 and epidermal growth factor receptors by tumor necrosis factor alpha.

Authors:  H Kalthoff; C Roeder; J Gieseking; I Humburg; W Schmiegel
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.